| Literature DB >> 26713110 |
Rongjun He1, Zhi-Hong Yu1, Ruo-Yu Zhang1, Li Wu1, Andrea M Gunawan1, Zhong-Yin Zhang1.
Abstract
mPTPB is a virulent phosphatase from Mycobacterium tuberculosis and a promising therapeutic target for tuberculosis. To facilitate mPTPB-based drug discovery, we identified α-sulfophenylacetic amide (SPAA) from cefsulodin, a third generation β-lactam cephalosporin antibiotic, as a novel pTyr pharmacophore for mPTPB. Structure-guided and fragment-based optimization of SPAA led to the most potent and selective mPTPB inhibitor 9, with a K i of 7.9 nM and more than 10,000-fold preference for mPTPB over a large panel of 25 phosphatases. Compound 9 also exhibited excellent cellular activity and specificity in blocking mPTPB function in macrophage. Given its novel structure, modest molecular mass, and extremely high ligand efficiency (0.46), compound 9 represents an outstanding lead compound for anti-TB drug discovery targeting mPTPB.Entities:
Keywords: Protein tyrosine phosphatase; antituberculosis; mPTPB inhibitor; pTyr mimetics
Year: 2015 PMID: 26713110 PMCID: PMC4677373 DOI: 10.1021/acsmedchemlett.5b00373
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345